Abstract: Disclosed is a copper-niobium alloy for a medical biopsy puncture needle. A needle core and/or needle tube of the puncture needle are/is made of the copper-niobium alloy. The copper-chromium alloy includes the following components by mass: 5?Nb?15 and the balance of Cu. A copper alloy with designed components is obtained by combining a diamagnetic material Cu with paramagnetic Nb, and compared with existing medical stainless steel and titanium alloy, the copper alloy has greatly reduced magnetic susceptibility, and specifically, the artifact area and volume are also significantly reduced. In addition, the blank of use of the copper alloy in medical biopsy paracentesis is filled.

Abstract: The present invention provides a method, device and computer-readable medium of a seamless switch between resolutions based on software and hardware decoding and belongs to a field of the Internet technology.

Abstract: The present disclosure provides a fiber membrane and a preparation method and use thereof, and belongs to the field of biological materials. The fiber membrane includes a fiber with a core-shell structure, where a core of the fiber includes simvastatin and a first spinnable polymer, and a shell of the fiber includes hydroxyapatite and a second spinnable polymer. In the fiber, a release of the simvastatin mainly depends on a rate of water invasion. After water invades the fiber, the simvastatin in the fiber leaves the fiber with the diffusion of water. In the present disclosure, a barrier function of the shell prevents moisture from entering the core. Therefore, the simvastatin in the core cannot leave the fiber with the diffusion of water molecules in an early stage, and a release rate of drugs is slowed down in the early stage, thereby controlling sustained release of the drugs.

Abstract: The present disclosure provides a hydrophilic fiber membrane with a sustained-release drug, and belongs to the field of biological materials. The present disclosure provides a hydrophilic fiber membrane with a sustained-release drug, including a fiber with a core-shell structure, where a core of the fiber includes curcumin and a first spinnable polymer, and a shell of the fiber includes polyethylene glycol and a second spinnable polymer; and in the shell, the polyethylene glycol and the second spinnable polymer have a mass ratio of not greater than 1:12. In the present disclosure, the fiber membrane has a core-shell structure, the curcumin is provided in the core, and the shell prevents a rapid release of the curcumin in an early stage, thereby delaying a release rate of the curcumin to prevent the drug from forming a burst release in the early stage and causing toxic reactions.

Abstract: Provided a method for in situ synthesizing ultrafine and highly loaded Ag NPs on the surface of tannin-coated phenolic resin microspheres, the method comprises: (1) preparing phenolic resin microspheres by hydrothermal solvent method; (2) stirring a mixed phase of the phenolic resin microspheres and a tannin solution under a alkaline condition at room temperature to obtain tannin-coated phenolic resin microspheres; (3) adding the tannin-coated phenolic resin microspheres to a silver ammonia solution to obtain a composite that being loaded with Ag NPs on the surface of tannin-coated phenolic resin microspheres. Ag NPs in the composite are ultrafine and highly loaded. The raw materials of the method are low price, and the preparation process is extremely simple and environmentally friendly. In addition, the tannin coating technology is also suitable for other nanomaterials, such as SiO2, TiO2 and Fe3O4, etc., and has good application prospects and market potential.

Abstract: Embodiments of the disclosure provide a semiconductor structure and a method for manufacturing the same. The method includes the following operations. A substrate is provided, in which the substrate includes a device region and an alignment region. A layer stack covering the device region and the alignment region is formed on the substrate, in which the layer stack at least includes a first conductive layer as a bottom layer of the layer stack, and a material of the first conductive layer includes a semiconductor material. The layer stack is etched to respectively form first trenches in the device region and second trenches in the alignment region which penetrate through the layer stack, in which the second trenches and the layer stack located between the second trenches form alignment marks.

Abstract: An optical system, an optocoupler, and an isolation device are provided. The disclosed optical system includes at least one photodetector that receives light energy and converts the light energy into one or more electrical signals. The disclosed optical system further includes a comparator module that receives the one or more electrical signals from the at least one photodetector and compares the one or more electrical signals against two different reference values to determine whether a power supply fault condition has occurred for a light source that emitted the light energy and to determine a logic signal conveyed to the at least one photodetector via the light energy emitted by the light source.

Abstract: An optical system, an optocoupler, and an isolation device are provided. The disclosed optical system includes at least one photodetector that receives light energy and converts the light energy into one or more electrical signals. The disclosed optical system further includes a comparator module that receives the one or more electrical signals from the at least one photodetector and compares the one or more electrical signals against two different reference values to determine whether a power supply fault condition has occurred for a light source that emitted the light energy and to determine a logic signal conveyed to the at least one photodetector via the light energy emitted by the light source.

Abstract: The present invention relates to methods of treatment for Parkinson Disease (PD) in a person by identifying gene variants which may indicate a more favorable response to specific medicaments, thereby allowing for personalized or individualized treatment. The present invention relates to a method of screening for a genetic predisposition to PD in a person. The present invention is also directed to a method of testing a person for the presence of particular gene variants, wherein the presence of a gene variant indicates a higher predisposition to PD, and the absence of a gene variant indicates a lower predisposition to PD, compared to a control sample. The present invention further relates to methods and kits for treating, or inhibiting the development of, PD in a person. The present invention is also directed to a method of identifying the heritage of an individual based on the genetic profile of the individual.